In particular, interleukin 6 expression has been associated with worse outcomes in patients with NSCLC treated with EGFR-TKIs, which may induce tumor refractoriness to EGFR-TKIs via JAK–STAT3 signaling activation or suppression of anti-tumor immune responses [12,13,14,15]. Here, IL6 is linked to neoplasm.